CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 233 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $640,470 | -21.5% | 41,347 | -19.2% | 0.00% | -25.0% |
| Q1 2024 | $815,448 | +3.7% | 51,157 | +9.4% | 0.00% | 0.0% |
| Q4 2023 | $786,378 | +47.0% | 46,780 | +2.2% | 0.00% | +33.3% |
| Q3 2023 | $535,005 | +46584.6% | 45,766 | -19.5% | 0.00% | -66.7% |
| Q4 2022 | $1,146 | -99.9% | 56,885 | -21.8% | 0.01% | 0.0% |
| Q3 2022 | $1,018,000 | – | 72,720 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 17,875,655 | $94,920,000 | 9.39% |
| TANAKA CAPITAL MANAGEMENT INC | 283,334 | $1,505,000 | 4.86% |
| GABLES CAPITAL MANAGEMENT INC. | 490,564 | $2,606,000 | 1.84% |
| MANGROVE PARTNERS IM, LLC | 2,508,838 | $13,322,000 | 1.61% |
| Broadfin Capital, LLC | 880,303 | $4,674,000 | 0.86% |
| Atom Investors LP | 1,012,355 | $5,376,000 | 0.37% |
| Capital Impact Advisors, LLC | 179,868 | $948,000 | 0.36% |
| KNOTT DAVID M | 151,415 | $804,000 | 0.34% |
| EMERALD ADVISERS, LLC | 1,175,958 | $6,244,000 | 0.29% |
| CADENCE CAPITAL MANAGEMENT LLC | 371,075 | $1,970,000 | 0.28% |